Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe

James Sipthorp1, Honorine Lebraud2, Rebecca Gilley1

  • 1Signalling Laboratory, The Babraham Institute , Babraham Research Campus, Cambridge CB22 3AT, U.K.

Bioconjugate Chemistry
|April 29, 2017
PubMed

Insights

Researchers developed a novel, less-invasive method to visualize Extracellular signal-Regulated Kinase 1/2 (ERK1/2) in cancer cells. This technique uses click chemistry to track ERK1/2 activity, offering new insights into targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The RAS-RAF-MEK-ERK pathway is crucial in cancer, with RAS mutations found in approximately 30% of human cancers.
  • Understanding ERK1/2 behavior during small-molecule inhibition is vital due to emerging ERK1/2 inhibitors in clinical trials.

Purpose of the Study:

  • To develop and validate a less-invasive method for visualizing endogenous ERK1/2.
  • To assess the utility of click chemistry for tracking ERK1/2 in cellular imaging.

Main Methods:

  • Utilized a two-step inverse electron demand Diels-Alder cycloaddition (click chemistry).
  • Employed a previously developed trans-cyclooctene-tagged covalent ERK1/2 inhibitor.
  • Performed imaging experiments using a tetrazine-tagged fluorescent dye.

Main Results:

  • Successfully visualized endogenous ERK1/2 in cells.
  • Confirmed "on-target" staining by over-expressing DUSP5, a nuclear ERK1/2 phosphatase.
  • Identified limitations encountered during the imaging process.

Conclusions:

  • The developed click chemistry approach enables visualization of endogenous ERK1/2.
  • This method provides a less-invasive alternative to traditional protein visualization techniques.
  • Further optimization is needed, but the approach shows promise for studying ERK1/2 in cancer research.